178 related articles for article (PubMed ID: 31851518)
1. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-
Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E
J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518
[TBL] [Abstract][Full Text] [Related]
2. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
4. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Nakamura K; Karmokar A; Farrington PM; James NH; Ramos-Montoya A; Bickerton SJ; Hughes GD; Illidge TM; Cadogan EB; Davies BR; Dovedi SJ; Valge-Archer V
Clin Cancer Res; 2021 Aug; 27(15):4353-4366. PubMed ID: 34011558
[TBL] [Abstract][Full Text] [Related]
6. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.
Oza V; Ashwell S; Brassil P; Breed J; Ezhuthachan J; Deng C; Grondine M; Horn C; Liu D; Lyne P; Newcombe N; Pass M; Read J; Su M; Toader D; Yu D; Yu Y; Zabludoff S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2330-7. PubMed ID: 22342147
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
Boezio AA; Copeland KW; Rex K; K Albrecht B; Bauer D; Bellon SF; Boezio C; Broome MA; Choquette D; Coxon A; Dussault I; Hirai S; Lewis R; Lin MH; Lohman J; Liu J; Peterson EA; Potashman M; Shimanovich R; Teffera Y; Whittington DA; Vaida KR; Harmange JC
J Med Chem; 2016 Mar; 59(6):2328-42. PubMed ID: 26812066
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
[TBL] [Abstract][Full Text] [Related]
12. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Berger M; Wortmann L; Buchgraber P; Lücking U; Zitzmann-Kolbe S; Wengner AM; Bader B; Bömer U; Briem H; Eis K; Rehwinkel H; Bartels F; Moosmayer D; Eberspächer U; Lienau P; Hammer S; Schatz CA; Wang Q; Wang Q; Mumberg D; Nising CF; Siemeister G
J Med Chem; 2021 Sep; 64(17):12723-12737. PubMed ID: 34428039
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM; Batey MA; Zhao Y; Jenkins H; Richardson CJ; Cano C; Tavecchio M; Barbeau J; Bardos J; Cornell L; Griffin RJ; Menear K; Slade A; Thommes P; Martin NM; Newell DR; Smith GC; Curtin NJ
Mol Cancer Ther; 2012 Aug; 11(8):1789-98. PubMed ID: 22576130
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines.
Ihmaid SK; Al-Rawi JM; Bradley CJ; Angove MJ; Robertson MN
Eur J Med Chem; 2012 Nov; 57():85-101. PubMed ID: 23059543
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
17. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
18. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
Pasquier B; El-Ahmad Y; Filoche-Rommé B; Dureuil C; Fassy F; Abecassis PY; Mathieu M; Bertrand T; Benard T; Barrière C; El Batti S; Letallec JP; Sonnefraud V; Brollo M; Delbarre L; Loyau V; Pilorge F; Bertin L; Richepin P; Arigon J; Labrosse JR; Clément J; Durand F; Combet R; Perraut P; Leroy V; Gay F; Lefrançois D; Bretin F; Marquette JP; Michot N; Caron A; Castell C; Schio L; McCort G; Goulaouic H; Garcia-Echeverria C; Ronan B
J Med Chem; 2015 Jan; 58(1):376-400. PubMed ID: 25402320
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
20. Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor.
De Pascale M; Bissegger L; Tarantelli C; Beaufils F; Prescimone A; Mohamed Seid Hedad H; Kayali O; Orbegozo C; Raguž L; Schaefer T; Hebeisen P; Bertoni F; Wymann MP; Borsari C
Eur J Med Chem; 2023 Feb; 248():115038. PubMed ID: 36634458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
